Immunex sells cancer drug to Schering AG for US$380 M
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 24 (Table of Contents)
Published: 2 May-2002
DOI: 10.3833/pdr.v2002.i24.1062 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Immunex entered into a definite agreement to sell its Leukine® (sargramostim) business to Schering AG for US$380 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018